All of the following are false about Tenapanor except:
Tenapanor Small molecule medication approved in September 2019 for the treatment of constipation-predominant irritable bowel-syndrome (IBS-C). MOA - Inhibitor of the sodium/hydrogen exchanger isoform 3 (NHE3) transpoer First and currently only medication within its class By inhibiting NHE3 on the apical surface of the enterocytes, tenapanor reduces absorption of sodium from the small intestine and colon, Resulting in an increase in water secretion into the intestinal lumen, which accelerates intestinal transit time and results in a softer stool consistency. Recommended dosage in adults - 50 mg orally twice daily- prior to breakfast or the first meal of the day and immediately prior to dinner C/I Patients< 6 years of age due to the risk of serious dehydration, Patients with known or suspected mechanical gastrointestinal obstruction
It is indicated for use in diarrhoea predominant IBS
Can be used in children < 6 years
Acts by inhibiting NHE3 on enterocytes, reducing reabsorption of sodium in small intestine
Constipation is a serious adverse effect
Gastro-Intestinal Tract